Emicizumab in pediatric hemophilia: Bleeding and surgical outcomes from a single‐center retrospective study

2021 ◽  
Author(s):  
Clay T. Cohen ◽  
Rosa Diaz
Keyword(s):  
Retrospective Study ◽  
Surgical Outcomes ◽  
Single Center

scholarly journals Retrospective Study of Surgical Outcomes in 60 Patients with Crohn Disease from a Single Center in Poland

2021 ◽  
Vol 28 ◽  
Author(s):  
Karolina Majewska ◽  
Cezary Rusinowski ◽  
Beata Jabłońska ◽  
Dariusz Gołka ◽  
Sławomir Mrowiec
Keyword(s):  
Retrospective Study ◽  
Crohn Disease ◽  
Surgical Outcomes ◽  
Single Center

Abstract #1059 Prognostic Factors of Metastatic Thyroid Carcinoma: A Single Center Retrospective Study

2018 ◽  
Vol 24 ◽  
pp. 249
Author(s):  
David Broome ◽  
Gauri Bhuchar ◽  
Ehsan Fayazzadeh ◽  
James Bena ◽  
Christian Nasr
Keyword(s):  
Prognostic Factors ◽  
Retrospective Study ◽  
Thyroid Carcinoma ◽  
Single Center

Computed Tomography-Guided Percutaneous Infiltrations for Piriformis Syndrome: A Single-Center Retrospective Study

2020 ◽  
Vol 30 (2) ◽  
pp. 113-118
Author(s):  
D. Filippiadis ◽  
C. Gkizas ◽  
G. Velonakis ◽  
Dimitrios A. Flevas ◽  
Z. T. Kokkalis ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Retrospective Study ◽  
Piriformis Syndrome ◽  
Single Center

scholarly journals The Dose of Somatostatin Analogues during Pre-Surgical Treatment Is a Key Factor to Achieve Surgical Remission in Acromegaly

Endocrines ◽  
2021 ◽  
Vol 2 (3) ◽  
pp. 241-250
Author(s):  
Marta Araujo-Castro ◽  
Eider Pascual-Corrales ◽  
Héctor Pian ◽  
Ignacio Ruz-Caracuel ◽  
Alberto Acitores Cancela ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Surgical Treatment ◽  
Surgical Outcomes ◽  
Pituitary Adenomas ◽  
Somatostatin Analogues ◽  
Beneficial Effects ◽  
Key Factor ◽  
Long Acting ◽  
First Time ◽  
Endocrine Complications

Purpose: to determine whether pre-surgical treatment using long-acting somatostatin analogues (SSAs) may improve surgical outcomes in acromegaly. Methods: retrospective study of 48 patients with acromegaly operated by endoscopic transsphenoidal approach and for first time. Surgical remission was evaluated based on the 2010 criteria. Results: most patients, 83.3% (n = 40), harbored macroadenomas and 31.3% (n = 15) invasive pituitary adenomas. In this case, 14 patients were treated with lanreotide LAR and 6 with octreotide LAR, median monthly doses of 97.5 [range 60–120] and 20 [range 20–30] mg, respectively, for at least 3 months preoperatively. Presurgical variables were comparable between pre-treated and untreated patients (p > 0.05). Surgical remission was more frequent in those pre-treated with monthly doses ≥90 mg of lanreotide or ≥30 mg of octreotide than in untreated or pre-treated with lower doses (OR = 4.64, p = 0.025). However, no differences were found between pre-treated and untreated patients when lower doses were included or between those treated for longer than 6 months compared to those untreated or pre-treated for shorter than 6 months. Similarly, no differences were found either in terms of surgical or endocrine complications (OR = 0.65, p = 0.570), independently of the doses and the duration of SSA treatment (p > 0.05). Conclusions: the dose of SSAs is a key factor during pre-surgical treatment, since the beneficial effects in surgical remission were observed with monthly doses equal or higher than 90 mg of lanreotide and 30 mg of octreotide, but not with lower doses.

Sign in / Sign up

Export Citation Format

Share Document